Inflammation and atherosclerosis are involved in various cardiovascular diseases, and identifying whether VEGFR-2 signaling is involved in this mechanotransductive pathway is an essential step in harnessing the receptor to treat disease states. This evidence concerns the gene KDR and atherosclerosis.